ADCendo
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
ADCendo has raised $261M across 4 rounds. Its most recent round was a Series C of $75.0M in Apr 2026. Full funding history, investors, and team are detailed below.
Funding history
4 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 3 earlier rounds — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
ADCendo is featured in
Similar companies
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer in the diagnosis and treatment of cancer patients. In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.
Alcolase is a Danish life science start-up that specializes in alcohol flushing.
ENZIDIA is unleashing the biomanufacturing revolution with an enzyme acceleration revolution
Gefjon Pharma is a biopharmaceutical company focused on developing innovative solutions to combat antimicrobial resistance and improve animal health, particularly in poultry production.
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly Parkinson's disease.
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Pioneering new sustainable bio-based ingredients
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.
EvodiaBio is a company in the bio-industrial sector that develops eco-friendly fragrances for the food and beverage sectors. Established in 2021, the company is located in Copenhagen, in the Capital Region.
Fida Biosystems is a technology that provides the detection and characterization of proteins and nanoparticles under native conditions. It is a company that operates in the field of biotechnology and provides nanoparticle and protein analysis services.
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.